Horizon Pharma Plc (NASDAQ:HZNP) Shareholder Broadfin Capital Llc Upped Its Position by $31.70 Million as Price Declined

May 17, 2018 - By Eula Gilbert

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Corporate LogoBig Money Sentiment increased to 1.04 in 2017 Q4. It has change of 0.04, from 2017Q3’s 1. The ratio increased due to HZNP positioning: 30 sold and 53 reduced. 33 funds took stakes and 53 increased stakes. Investors holded 132.29 million in 2017Q3 but now own 128.65 million shares or 2.76% less. Schwab Charles Invest Incorporated stated it has 878,801 shs. Royal Bankshares Of Canada reported 1,180 shs or 0% of all its holdings. Teacher Retirement Systems Of Texas, a Texas-based fund reported 54,354 shs. Plante Moran Advsr Lc holds 1,500 shs or 0.01% of its capital. Nuveen Asset Mgmt Ltd Com has invested 0.01% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Numeric Investors Ltd Liability Corporation has invested 0.01% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Jw Asset Management Ltd Company reported 270,775 shs stake. Parametric Port Associates Lc accumulated 0.01% or 660,689 shs. Sterling Capital Management Limited Liability invested in 91,793 shs. Nomura reported 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Tekla Management Lc holds 0.09% of its capital in Horizon Pharma Public Limited Company (NASDAQ:HZNP) for 162,900 shs. Advisory Net Limited Liability has invested 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Massachusetts Services Company Ma invested in 0% or 93,643 shs. Prudential Public Limited Liability Corporation holds 444,796 shs or 0.02% of its capital. Kopp Investment Advisors Limited Liability Com holds 1.54% or 105,126 shs.

Based on the latest 2018Q1 report from the SEC, Broadfin Capital Llc upped its stake in Horizon Pharma Plc (NASDAQ:HZNP) by 754.73%. Horizon Pharma Plc (NASDAQ:HZNP) declined 6.58% with the market as Broadfin Capital Llc bought 2.26 million shares. It held 2.56M shares of Horizon Pharma Plc (NASDAQ:HZNP) at the end of 2018Q1, valued at $36.41M, up from 300,000 last quarter. $2.47 billion is the MC of Horizon Pharma Plc. Ticker’s shares touched $14.97 during the last trading session after 0.60% change.Horizon Pharma Public Limited Company has volume of 1.01 million shares. Since May 17, 2017 HZNP has declined 6.20% and is downtrending. HZNP underperformed by 17.75% the S&P500.

It decreased Heron Therapeutics Inc (NASDAQ:HRTX) position by 447,102 shares to 1.58 million shares, and cut its Mirati Therapeutics Inc (NASDAQ:MRTX) stake.

Broadfin Capital is located in New York City and was founded by Kevin Kotler. Prior to Broadfin, Kotler could be found working for firms such as ING Barings, the Galleon Group, and ABN AMRO. Broadfin Capital Llc is a New York-based hedge fund that was founded by Kevin Kotler. It had more than $1.26 billion assets under management in December, 2014. Taken from Broadfin Capital latest Adv, the fund reported to have 10 full and part-time employees. Among which 5 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Coverage

Total analysts of 6 have positions in Horizon Pharma Inc (NASDAQ:HZNP) as follows: 5 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 83%. Since November 30, 2017 according to StockzIntelligence Inc Horizon Pharma Inc has 11 analyst reports. On Friday, March 2 the stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) has “Equal-Weight” rating given by Morgan Stanley. The company rating was maintained by Mizuho on Wednesday, April 11. On Tuesday, January 30 the stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) earned “Buy” rating by Piper Jaffray. In Wednesday, February 28 report Cantor Fitzgerald maintained it with “Buy” rating and $17.0 target. On Monday, May 7 Mizuho maintained the shares of HZNP in report with “Buy” rating. On Wednesday, February 28 Cowen & Co maintained Horizon Pharma Public Limited Company (NASDAQ:HZNP) rating. Cowen & Co has “Buy” rating and $24.0 target. On Sunday, April 15 the stock has “Buy” rating by Cantor Fitzgerald. On Thursday, March 1 the stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) has “Buy” rating given by UBS. On Wednesday, February 28 the stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) has “Buy” rating given by Piper Jaffray. In Thursday, November 30 report UBS maintained it with “Buy” rating and $20.0 target.

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally.The company has $2.47 billion market cap. The companyÂ’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout.Currently it has negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: